Gregory B. Brown, M.D. has served as a member of the Company’s board of directors since March 2007. Dr. Brown is currently the Chief Executive Officer and member of the Board of Directors of Memgen, Inc., a private clinical-stage biotechnology company. He is a co-founder of HealthCare Royalty Partners, or HCRx, and is a member of that firm’s Senior Advisor Board. Educated as a transplantation immunologist and trained as a thoracic and vascular surgeon, Dr. Brown practiced thoracic and vascular surgery in a community setting where he also founded and led a health maintenance organization. Before co-founding HCR Partners, Dr. Brown was a partner at Paul Capital Partners, where he co-managed that firm’s royalty investments. Prior to beginning his principal investment career in 2003, Dr. Brown was co-head of investment banking and head of healthcare at Adams, Harkness & Hill (now Canaccord Genuity) and a ranked biotechnology research analyst at Vector Securities International. Dr. Brown holds a BA from Yale University, an M.D. from SUNY Upstate Medical Center and an MBA from Harvard Business School. Our Board believes that Dr. Brown’s extensive senior experience as a leader in the pharmaceutical and biotechnology industry, experience on the boards of public and private companies, as well as his medical background, qualifies him to serve on our Board of Directors.